Patients with an increased frequency of tumor-infiltrating PD-L1hi Tregs showed high PD-1/PD-L1 pathway dependence, and improved CD8+ T-cell responses following PD-1 inhibition. The gene discussed is CD8A; the disease is neoplasm.